Publication Date

2019

Journal Title

Clin Lymphoma Myeloma Leuk

Abstract

© 2019 A pooled analysis of 1238 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma from three phase 3 studies found that genomic risk factors were not associated with shorter progression-free survival (PFS) or overall survival for patients treated with ibrutinib. Ibrutinib-treated patients with del(11q) were found to have a longer PFS than those without del(11q). These results suggest less prognostic relevance for certain genomic risk factors with ibrutinib treatment.

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

General Internal Medicine

PMID

31447270

DOI

10.1016/j.clml.2019.07.004


Share

COinS